Pharmacological correction of experimentally induced osteoporosis complicated by type 2 diabetes mellitus

Abstract

BACKGROUND: Osteoporosis remains one of the most important medical problems worldwide with significant economic consequences. The development of new drugs based on unique biologically active compounds can contribute significantly to osteoporosis management.

AIM: To evaluate the osteogenesis processes by evaluating bone-remodeling markers in the blood serum during the treatment of experimental osteoporosis complicated by type 2 diabetes mellitus.

MATERIALS AND METHODS: The study was performed on an experimental model of osteoporosis, followed by the induction of type 2 diabetes mellitus, using biochemical methods to analyze markers of osteoporosis in the blood serum.

RESULTS: The results of the analysis of bone remodeling markers revealed that the antiosteoporotic activity of a composite preparation based on succinic acid salts is dependent on glucose metabolism disorders such as diabetes mellitus. The high efficacy of the new drug in monotherapy and combination with vitamin D₃ in the activation of osteogenesis in experimental osteoporosis was balanced by impaired metabolic processes in type 2 diabetes mellitus.

CONCLUSIONS: The results indicate the dependence of the pharmacological effectiveness of the antiosteoporosis agent on metabolic disorders, such as type 2 diabetes mellitus, in female rats with experimental osteoporosis.

Keywords

osteoporosis / experimental model / markers of osteogenesis / bone tissue remodeling / antiosteoporosis agent / diabetes mellitus type 2

References

[1] Lesnyak OM. Osteoporosis audit in the Russian Federation. Preventive Medicine. 2011;(2):7–10. (In Russ.) EDN: PUGUSZ

[2] Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации // Профилактическая медицина. 2011. № 2. С. 7–10. EDN: PUGUSZ

[3] Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int. 2000;11(7):556–561. doi: 10.1007/s001980070075

[4] Cauley J.A., Thompson D.E., Ensrud K.C., et al. Risk of mortality following clinical fractures // Osteoporosis Int. 2000. Vol. 11, N. 7. Р. 556–561. doi: 10.1007/s001980070075

[5] Kulakov VI, Savelieva GM, Manukhin IB. editors. Gynecology. National guide. Moscow: GEOTAR-Media; 2009. 670 p. (In Russ.)

[6] Гинекология. Национальное руководство / под ред. В.И. Кулакова, Г.М. Савельевой, И.Б. Манухина. Москва: ГЭОТАР-Медиа, 2009. 670 с.

[7] Riggz BL, Melton D. Osteoporosis. Etiology, diagnosis, treatment. Moscow: Binom; 2000. P. 309–313. (In Russ.)

[8] Риггз Б.Л., Мелтон Д. Остеопороз. Этиология, диагностика, лечение. Москва: Бином, 2000. С. 309–313.

[9] Kondrashova MN, Dynnik VV, Kaminsky YG, et al. editors. Mitochondrial processes in the temporal organization of life activity. 1978. 182 p. (In Russ.)

[10] Митохондриальные процессы во временной организации жизнедеятельности / под ред. М.Н. Кондрашовой, В.В. Дынника, Ю.Г. Каминский, и др. Пущино, 1978. 182 с.

[11] Mayevsky EI, Grishina EV, Haustova YaV, et al. Once again about drugs containing succinate. Gastroenterology of St. Petersburg. 2017;(1):91–92. (In Russ.) EDN: YRHBUZ

[12] Маевский Е.И., Гришина Е.В., Хаустова Я.В., и др. Вновь о препаратах, содержащих сукцинат // Гастроэнтерология Санкт-Петербурга. 2017. № 1. С. 91–92. EDN: YRHBUZ

[13] Vasilieva AA, Simonova MA, Bairamov AA, et al. Correction of the functional state of female rats after unilateral ovariectomy using a succinate containing composition. Cardiometry. 2017;(10):86–92. EDN: YPOTOX doi: 10.12710/cardiometry.2017.8692

[14] Vasilieva A.A., Simonova MA, Bairamov AA., et al. Correction of the functional state of female rats after unilateral ovariectomy using a succinate containing composition // Cardiometry. 2017. N. 10. P. 86–92. EDN: YPOTOX doi: 10.12710/cardiometry.2017.8692

[15] Bairamov AA, Maevskii EI, Shabanov PD. Correction of bone remodeling in experimental osteoporosis. Reviews on Clinical Pharmacology and Drug Therapy. 2019;17(4):43–50. (In Russ.) EDN: MZRJFH doi: 10.17816/RCF17443-50

[16] Байрамов А.А., Маевский Е.И., Шабанов П.Д. Коррекция костного ремоделирования при экспериментальном остеопорозе // Обзоры по клинической фармакологии и лекарственной терапии. 2019. Т. 17, № 4. С. 43–50. EDN: MZRJFH doi: 10.17816/RCF17443-50

[17] Lisovsky DA, Mamina NSh, Droblenkov AV, et al. Morphological and biochemical characteristics of osteogenesis during drug therapy for experimental osteoporosis. Translational Medicine. 2023;10(6): 535–548. EDN: LOUQMK doi: 10.18705/2311-4495-2023-10-6-535-548

[18] Лисовский Д.А., Мамина Н.Ш., Дробленков А.В., и др. Морфологическая и биохимическая характеристика остеогенеза при медикаментозной терапии экспериментального остеопороза // Трансляционная медицина. 2023. Т. 10, № 6. С. 535–548. EDN: LOUQMK doi: 10.18705/2311-4495-2023-10-6-535-548

[19] Wallander M, Axelsson KF, Nilsson AG, et al. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: A study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res. 2017;32(3):449–460. doi: 10.1002/jbmr.3002

[20] Wallander M., Axelsson K.F., Nilsson A.G., et al. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: A study from the fractures and fall injuries in the elderly cohort (FRAILCO) // J Bone Miner Res. 2017. Vol. 32, N. 3. P. 449–460. doi: 10.1002/jbmr.3002

[21] Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocrinol Metab. 2006;91(9):3404–3410. doi: 10.1210/jc.2006-0614.

[22] Bonds D.E., Larson J.C., Schwartz A.V., et al. Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study // J Clin Endocrinol Metab. 2006. Vol. 91, N. 9. P. 3404–3410. doi: 10.1210/jc.2006-0614.

[23] Levitsky AP, Makarenko OA, Denga OV, et al. Experimental methods of osteogenesis stimulators research: Methodical recommendations. Kiev: Avicenna; 2005. С. 31–38. (In Russ.)

[24] Левицкий А.П., Макаренко О.А., Деньга О.В., и др. Экспериментальные методы исследования стимуляторов остеогенеза: Методические рекомендации. Киев: Авиценна, 2005. С. 31–38.

[25] Frolkis VV, Povorozniuk VV, Evtushenko OA, Grigorieva NV. Experimental osteoporosis. Doctor. 2003;(6):48–52. (In Russ.)

[26] Фролькис В.В., Поворознюк В.В., Евтушенко О.А., Григорьева Н.В. Экспериментальный остеопороз // Doctor. 2003. № 6. С. 48–52.

[27] Bairamov AA, Mamina NSH, Karonova TL, Shabanov PD. Possibilities of in vivo validation of a model of experimental osteoporosis. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(4): 365–367. (In Russ.) EDN: OUJNZD doi: 10.7816/RCF184365-367

[28] Байрамов А.А., Мамина Н.Ш., Каронова Т.Л., Шабанов П.Д. Возможности прижизненной валидации модели экспериментального остеопороза // Обзоры по клинической фармакологии и лекарственной терапии. 2020. Т. 18. № 4. С. 365–367. EDN: OUJNZD doi: 10.17816/RCF184365-367

[29] Bayrasheva VK, Babenko AY, Dobronravov VA, et al. Uninephrectomized high-fat-fed nicotinamide-streptozotocininduced diabetic rats: A model for the investigation of diabetic nephropathy in type 2 diabetes. J Diabetes Res. 2016;2016:8317850. doi: 10.1155/2016/8317850

[30] Bayrasheva V.K., Babenko A.Y., Dobronravov V.A., et al. Uninephrectomized high-fat-fed nicotinamide-streptozotocininduced diabetic rats: A Model for the investigation of diabetic nephropathy in type 2 diabetes // J Diabetes Res. 2016. Vol. 2016. P. 8317850. doi: 10.1155/2016/8317850

[31] Simanenkova A, Minasian S, Karonova T, et al. Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance. Sci Rep. 2021;11(1):6700. doi: 10.1038/s41598-021-86132-2

[32] Simanenkova A., Minasian S., Karonova T., et al. Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance // Sci Rep. 2021. Vol. 11, N. 1. P. 6700. doi: 10.1038/s41598-021-86132-2

[33] Тimkina NV, Semenova NY, Simanenkova AV, et al. Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause. Diabetes Mellitus. 2023;26(2):145–156. (In Russ.) EDN: QWCBWH doi: 10.14341/DM12967

[34] Тимкина Н.В., Семенова Н.Ю., Симаненкова А.В., и др. Влияние терапии современными сахароснижающими препаратами на показатели костного обмена в условиях экспериментальной модели сахарного диабета и овариэктомии // Сахарный диабет. 2023. Т. 26, № 2. С. 145–156. EDN: QWCBWH doi: 10.14341/DM12967

[35] Cao B, Li R, Tian H, et al. Effect on glycemia in rats with type 2 diabetes induced by streptozotocin: low-frequency electro-pulse needling stimulated Weiwanxiashu (EX-B3) and Zusanli (ST 36). J Tradit Chin Med. 2016;36(6):768–778. doi: 10.1016/s0254-6272(17)30013-4

[36] Cao B., Li R., Tian H., et al. Effect on glycemia in rats with type 2 diabetes induced by streptozotocin: low-frequency electro-pulse needling stimulated Weiwanxiashu (EX-B3) and Zusanli (ST 36) // J Tradit Chin Med. 2016. Vol. 36, N. 6. P. 768–778. doi: 10.1016/s0254-6272(17)30013-4

[37] Patent RU 2582973/04.03.24. Byul. No. 34. Bairamov AA, Shabanov PD, Maevskii EI, et al. Anti-osteoporosis drug. Available from: https://yandex.ru/patents/doc/RU2582973C1_20160427 (In Russ.)

[38] Патент РФ на изобретение № 2582973/10.03.2015. Бюл. № 12. Байрамов А.А., Шабанов П.Д., Маевский Е.И., и др. Антиостеопорозное средство. Режим доступа: https://yandex.ru/patents/doc/RU2582973C1_20160427 Дата обращения: 04.03.2024.

[39] Bairamov AA, Mamina NSh, Lisovskiy DA, et al. Evaluation of osteogenesis processes against the background of experimental osteoporosis therapy. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(3):273–282. (In Russ.) EDN: BYNUCG doi: 10.17816/RCF567788

[40] Байрамов А.А., Мамина Н.Ш., Лисовский Д.А., и др. Оценка процессов остеогенеза на фоне терапии экспериментально индуцированного остеопороза // Обзоры по клинической фармакологии и лекарственной терапии. 2023. Т. 21. № 3. С. 273–282. EDN: BYNUCG doi: 10.17816/RCF567788

RIGHTS & PERMISSIONS

ECO-vector LLC